Nxera Pharma is the New Name for Sosei Group

• New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technology
• Sosei Group and its subsidiaries, Heptares Therapeutics and Idorsia Pharmaceuticals Japan and Korea, have all been renamed under the Nxera Pharma brand

Tokyo, Japan and Cambridge, UK, 1 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce the launch of its new company name, having received approval at the 34^th Ordinary General Meeting of Shareholders held on 27 March 2024. The Company’s new website can be found at www.nxera.life  

The Group name and those of its subsidiaries have changed as follows:

Old name	New name
Sosei Group Corporation	Nxera Pharma Co., Ltd.
Idorsia Pharmaceuticals Japan Ltd	Nxera Pharma Japan Co., Ltd.
Idorsia Pharmaceuticals Korea Co., Ltd	Nxera Pharma Korea Co., Ltd.
Heptares Therapeutics Ltd.	Nxera Pharma UK Limited

Chris Cargill, President & CEO of Nxera Pharma, commented: “Our name change from Sosei Group to Nxera Pharma marks a pivotal moment in our Company’s journey. It follows the significant growth and development of the business, which has been accelerated through several key strategic acquisitions in recent years, including Heptares Therapeutics in 2015 and the Idorsia Pharmaceuticals Japan and Korea businesses in 2023. These acquisitions have transformed the business into an integrated, technology powered, commercial-stage biopharmaceutical company focused on accelerating the development of life-changing medicines for patients in Japan and globally, by investing in science and technology.

“The Company decided that now is the optimal time to unify the business under a new name and bold brand. The name ’Nxera’ derives from the words ‘Next’ and ‘Era’ and our new motto – ‘Our Life’s Work is Life Itself’ – expresses our determination to lead the next era of medicine, leveraging our industry leading NxWave platform to drive advancements in our core disease areas of neurology, GI and immunology, metabolic disorders and rare diseases, in pursuit of new medicines for patients.”